Related Experiment Video
Updated: Apr 19, 2026

Measuring Single-Cell Aging with an Imaging-based Biomarker of Chromatin and Epigenetic Aging
Published on: January 30, 2026
[Immortal time bias in pharmacoepidemiological studies: definition, solutions and examples]
Jean-Luc Faillie1, Samy Suissa2
1Département de pharmacologie médicale et toxicologie, CHRU de Montpellier, Montpellier, France - Service de pharmacologie médicale et clinique, Equipe de recherche de pharmacoépidémiologie, INSERM UMR 1027, CHU de Toulouse, Faculté de médecine Université Paul Sabatier, Toulouse, France.
Abstract:
Among the observational studies of drug effects in chronic diseases, many of them have found effects that were exaggerated or wrong. Among bias responsible for these errors, the immortal time bias, concerning the definition of exposure and exposure periods, is relevantly important as it usually tends to wrongly attribute a significant benefit to the study drug (or exaggerate a real benefit). In this article, we define the mechanism of immortal time bias, we present possible solutions and illustrate its consequences through examples of pharmacoepidemiological studies of drug effects.
Related Concept Videos
Chronopharmacokinetics: Time-Dependent Pharmacokinetics
Time-dependent pharmacokinetics refers to non-cyclical changes in drug rate processes over a period of time. It can lead to nonlinear pharmacokinetics, where the relationship between drug concentration and time is not proportional. Non-cyclical...
Drug Accumulation During Multiple Dosing: Repetitive IV Injections
Measurement of Bioavailability: Pharmacodynamic Methods
Analysis of Population Pharmacokinetic Data
Pharmacokinetic–Pharmacodynamic Relationship: Problems
Dosage Regimens: Partial Pharmacokinetic Parameters

